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Abstract
Autonomic control of heart rate is mediated by cardioinhibitory
parasympathetic cholinergic neurons located in the brainstem
and stimulatory sympathetic noradrenergic neurons. During
embryonic development the survival and cholinergic phenotype
of brainstem autonomic neurons is promoted by brain-derived
neurotrophic factor (BDNF). We now provide evidence that
BDNF regulates heart rate by a mechanism involving increased
brainstem cardioinhibitory parasympathetic activity. Mice with a
BDNF haploinsufﬁciency exhibit elevated resting heart rate,
and infusion of BDNF intracerebroventricularly reduces heart
rate in both wild-type and BDNF+/ mice. The atropine-induced
elevation of heart rate is diminished in BDNF+/ mice and is
restored by BDNF infusion, whereas the atenolol-induced

decrease in heart rate is unaffected by BDNF levels, suggesting
that BDNF signaling enhances parasympathetic tone which is
diminished with BDNF haploinsufﬁciency. Whole-cell recordings from pre-motor cholinergic cardioinhibitory vagal neurons
in the nucleus ambiguus indicate that BDNF haploinsufﬁciency
reduces cardioinhibitory vagal neuron activity by increased
inhibitory GABAergic and diminished excitatory glutamatergic
neurotransmission to these neurons. Our ﬁndings reveal a
previously unknown role for BDNF in the control of heart rate by
a mechanism involving increased activation of brainstem
cholinergic parasympathetic neurons.
Keywords: BDNF, GABA, glutamate, nucleus ambiguus,
parasympathetic, vagus nerve.
J. Neurochem. (2014) 129, 573–580.

Brain-derived neurotrophic factor (BDNF) plays critical roles
in the development and plasticity of neuronal circuits
throughout the CNS (Huang and Reichardt 2001; Cohen
and Greenberg 2008). The production and release of BDNF
are tightly regulated spatially and temporally by distinct
activity-dependent mechanisms, with activation of excitatory
glutamatergic synapses being a prominent stimulus for
BDNF production in many neuronal populations (Balkowiec
and Katz 2002; Greenberg et al. 2009). The involvement of
BDNF in synaptic plasticity has been most extensively
studied in the hippocampus, where the gene and mRNA
encoding BDNF are up-regulated in response to cognitive
challenges (Young et al. 1999), and selective blockade of
BDNF production or of its high-afﬁnity receptor trkB impairs
learning and memory (Tyler et al. 2002; Vaynman et al.

2004; Liu et al. 2008). In addition, BDNF expression and
signaling are increased in response to physical exercise and
intermittent fasting, two environmental challenges that
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enhance synaptic plasticity and protect neurons against injury
and disease (see Mattson 2012 for review).
While its involvement in neuroplasticity in the hippocampus and cerebral cortex is established, it is not known
whether BDNF inﬂuences the function of autonomic neurons
in the brainstem that regulate heart rate. Two lines of
evidence suggested to us the possibility that BDNF plays a
role in heart rate regulation. First, exercise and intermittent
fasting that increase BDNF expression in many brain regions
(Lee et al. 2002; Wu et al. 2011) can also reduce resting
heart rate by increasing parasympathetic activity (Wan et al.
2003; Buchheit et al. 2010). Second, BDNF induces the
expression of choline acetyltransferase and increases acetylcholine synthesis and release in developing autonomic
neurons in culture (Yang et al. 2002; Zhou et al. 2004).
Pre-ganglionic cholinergic cardioinhibitory vagal neurons
(CVNs) in the nucleus ambiguus (NA) of the brainstem send
their axons through the vagus nerve to the heart, where they
release acetylcholine onto cardiac ganglia cells and thereby
reduce heart rate (Mendelowitz 1999; Wang et al. 2001a).
The NA CVNs receive excitatory glutamatergic input and
inhibitory GABAergic and glycinergic input (Wang et al.
2001b, 2009; Corbett et al. 2003; Jameson et al. 2008; Frank
et al. 2009). Brainstem vagal pre-ganglionic neurons,
including those in the NA, express the high-afﬁnity BDNF
receptor trkB (Zaidi et al. 2005; Liu and Wong-Riley 2013).
Here, we measured heart rates of wild-type and BDNF+/
mice in their home cages using telemetry probes, under control
conditions and during intracerebroventricular administration
of BDNF. BDNF protein levels are reduced by 30–70%
throughout the brain of BDNF+/ mice including the
brainstem (Duan et al. 2003; Abidin et al. 2006; Saylor et al.
2006). Together with patch-clamp recordings of excitatory
post-synaptic currents (EPSCs) and inhibitory post-synaptic
currents (IPSCs) in NA CVNs in brainstem slices from wildtype and BDNF+/ mice, our data suggest that BDNF
enhances the activity of parasympathetic NA CVNs and
thereby reduces heart rate.

Materials and methods
Animals and telemetry
Male heterozygous BDNFtm1Jae/J mutant (BDNF+/ ) and congenic
wild-type (WT) mice were purchased from Jackson Laboratories (Bar
Harbor, ME, USA). Mice were maintained under a 12 h light/12 h
dark cycle with food and water available ad libitum. All procedures
were approved by National Institute on Aging Animal Care and Use
Committee and complied with NIH guidelines. Telemetry transmitters TA10ETA-F20 (Data Sciences International, St. Paul, MN,
USA) were surgically implanted, as described previously (Wan et al.
2003) into wild-type and BDNF+/ mice (n = 6 for each genotype).
Two biopotential leads were routed subcutaneously lateral to midline
in the chest to monitor heart rate under various experimental
conditions. After transmitter implantation, mice were allowed to
recover for 1 month before initiating experiments.

Intracerebroventricular cannulation and i.c.v. infusion
Each mouse was implanted with a chronic guide cannula (Plastics
One Inc., Roanoke, VA, USA). The tip of the cannula was located in
the lateral ventricle (AP 0.25 mm, L 1.0 mm, depth 2.5 mm). An
injector (Plastics One Inc. VA) was adapted for intracerebroventricular (i.c.v.) infusion using a microdialysis pump (CMA Microdialysis, North Chelmsford, MA, USA) to provide a constant
infusion rate (0.5 lL/min).
Drug treatments and BDNF infusion
Recombinant human BDNF (ProSpec, Tany TechnoGene Itd.,
Ness-Ziona, Israel) was dissolved in sterile phosphate-buffered saline
(PBS) at the concentration of 3.0 lg/lL. Atropine methyl nitrate was
used as parasympathetic blocker (2 mg/kg, i.p.; MP Biomedcials
LLC, OH, USA). Atenolol was used as sympathetic blocker (MP
Biomedcials LLC, Santa Ana, CA, USA; 2 mg/kg, i.p.). Hexamethonium bromide was used as a ganglionic blocker (30 mg/kg, i.p.,
Sigma, MO, USA). Preliminary test injections with PBS (i.p.)
indicated that heat rate returned to baseline levels within 30 min after
injection. Therefore, change in heart rate was assessed as the
difference between the averaged heart rate recorded for 30 min prior
to injection and the averaged heart rate recorded between 30 min and
3 h after injection. PBS lacking or containing BDNF was infused
(i.c.v.) at a constant rate of 0.5 lL/min for 6 min. After infusion, the
injector remained in the guide cannula for additional 2 min before it
was removed. During the infusion, the mouse was under light
sedation provided by inhalation of 2% isoﬂurane, which allowed the
mouse to recover quickly for telemetric recording in its home cage.
Brainstem slice preparation and patch-clamp electrophysiological
recordings
Mice in a separate group were anesthetized via hypothermia and
cooled to ~ 4°C. Once heart rate signiﬁcantly slowed and no pain
reﬂex was elicited, a right thoracotomy was performed to expose the
heart, and the retrograde tracer rhodamine (XRITC; 2% solution,
20–50 lL, Invitrogen, Carlsbad, CA, USA) was injected into the
pericardial sac to label CVNs. After 3–5 days of recovery, animals
were overdosed with isoﬂurane and killed by cervical dislocation.
Brain tissue was collected and placed in 4°C physiological saline
buffer solution with the following composition: NaCl (140 mM),
KCl (5 mM), CaCl2 (2 mM), glucose (5 mM), and HEPES
(10 mM). Slices (400 lm) that included the nucleus ambiguus were
obtained and submerged in a recording chamber that allowed
perfusion above and below the slice with 22°C artiﬁcial CSF with the
following composition: NaCl (12 5 mM), KCl (3 mM), CaCl2
(2 mM), NaHCO3 (26 mM), glucose (5 mM), HEPES (5 mM) in
equilibrium with 95% O2–5% CO2. The osmolarity of all solutions
was 285–290 mOsm, and the pH was maintained between 7.35 and
7.4. CVNs were identiﬁed by the presence of the ﬂuorescent tracer
and differential interference contrast optics along with infrared
illumination and infrared-sensitive video detection cameras to gain
enhanced spatial resolution. Patch pipettes were ﬁlled with a solution
at pH 7.3 consisting of either KCl (150 mM), MgCl2 (4 mM), EGTA
(10 mM), Na-ATP (2 mM), HEPES (10 mM) or K-gluconic acid
(150 mM), HEPES (10 mM), EGTA (10 mM), MgCl2 (1 mM),
CaCl2 (1 mM) to isolate inhibitory or excitatory currents, respectively. Identiﬁed CVNs were voltage clamped at a holding potential
of 80 mV. To isolate only one neurotransmission for study,
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receptors for the other two major neurotransmitters were blocked.
Gabazine (Sigma-Aldrich, St. Louis, MO, USA; 25 lM) was used to
block GABAergic inhibitory neurotransmission, strychnine (1 lM)
was used to block glycinergic inhibitory neurotransmission, and D
(-)-2 amino-5-phosphopentanoic acid (AP5; 50 lM) and 6-cyano-7nitroquinoxaline-2,3-dione (CNQX; 50 lM) were used to block
glutamatergic excitatory neurotransmission. Threshold for IPSCs and
EPSCs was 5X RMS noise. Average frequency of EPSCs and IPSCs
was obtained from 2 min of stable recording. The scientist
performing the electrophysiological experiments was not informed
of the genotype of the animal until after the results were analyzed.
Statistical analysis
Repeated measures ANOVA and one- or two-way ANOVA were applied
to the telemetric recorded parameters and other results for which the
appropriate tests were applicable. For post hoc analysis the Student–
Newman–Keuls test or Student’s t-test was performed to determine
whether differences between two groups or treatments were
statistically signiﬁcant. p values less than or equal to 0.05 were
considered statistically signiﬁcant.

Results
Heart rate is elevated in BDNF+/ mice and is reduced by
ventricular BDNF infusion
Four weeks after implantation of transmitters, heart rate was
recorded continuously during a 24 h period in WT and
BDNF+/ mice in their home cages. The heart rate of
BDNF+/ mice was signiﬁcantly greater than WT mice
during both the dark and light periods (Fig. 1a).
WT mice that received an i.c.v. bolus infusion of BDNF
(3.0 lg) exhibited a signiﬁcantly lower heart rate compared
with those that received i.c.v. PBS (Fig. 1b). The lowering of
heart rate in response to i.c.v. BDNF was evident within 2 h of
infusion, persisted for 8–10 h, and then returned to the basal
level. BDNF+/ mice given an i.c.v. bolus of BDNF exhibited
a heart rate signiﬁcantly lower than those treated with i.c.v.
PBS (Fig. 1c). The heart rate lowering effect of i.c.v. BDNF
was evident within 30 min of infusion and persisted for 10 h.
A repeated ANOVA test for the ﬁrst 10 h after infusion revealed
that there were signiﬁcant effects of time (p < 0.05) and
treatment (PBS vs. BDNF, p < 0.05) such that BDNF infusion
resulted in a signiﬁcant lowering of heart rate compared with
PBS (Fig. 1b, c). There was also a signiﬁcant effect of
genotype on the BDNF effect on heart rate with the reduction
in heart rate being greater in the BDNF+/ mice (WT vs.
BDNF+/ mice, p < 0.05) (Fig. 1b, c).
BDNF enhances parasympathetic regulation of heart rate,
without affecting sympathetic tone or intrinsic heart rate
To elucidate the mechanism whereby BDNF lowers heart
rate, we measured heart rate in WT and BDNF+/ mice
during treatment with drugs that block cholinergic/parasympathetic (atropine) and b-adrenergic/sympathetic (atenolol)
autonomic inputs to the heart. Within 30 min of atropine
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administration, the heart rate of WT mice was increased by
approximately 200 bpm and then slowly decreased during
the next 2.5 h (Fig. 2a). The magnitude of the increase in
heart rate in response to atropine was signiﬁcantly less in
BDNF+/ mice compared with WT mice, suggesting a
lower level of parasympathetic activity in the BDNF+/
mice (Fig. 2). Treatment of mice with atenolol resulted in a
decrease in the heart rates of all mice; the heart rates were
reduced by more than 100 bpm at 1 and 2 h of atenolol
injection (Fig. 2). The heart rate responses to atenolol were
identical in WT and BDNF+/ mice, suggesting that BDNF
does not affect sympathetic activation of the heart. Finally, to
determine whether BDNF might affect intrinsic heart rate, we
measured heart rates of WT and BDNF+/ mice that were
treated with hexamethonium, a ganglionic blocker (Tucker
and Domino 1988). Heart rate was elevated in response to
hexamethonium in all mice, with no statistically signiﬁcant
differences between WT and BDNF+/ mice (Fig. 2).
Central BDNF infusion eliminates the difference in heart
rate response to atropine in BDNF+/ mice compared with
WT mice
Because of the reduced heart rate response to atropine in
BDNF+/ mice, without altered responses to atenolol or
hexamethonium, we determined whether i.c.v. infusion of
BDNF would restore the heart rate response to atropine.
Atropine was injected (i.p.) 3 h after BDNF infusion (3.0 lg/
3 lL, i.c.v.). The magnitude of the elevation of heart rate in
response to atropine was not different in WT and BDNF+/
that had been administered i.c.v. BDNF (Fig. 3), in contrast
to a signiﬁcantly lower heart rate response to atropine in
BDNF+/ mice not administered BDNF (Fig. 2a). These
ﬁndings indicate that BDNF haploinsufﬁciency results in
reduced parasympathetic control of heart rate and that this
abnormality can be reversed by CNS BDNF administration.
Evidence that BDNF increases excitatory activation of
brainstem cardiac vagal neurons
The results of measurements of heart rate in BDNF+/ mice,
and mice administered i.c.v. BDNF suggested that BDNF
enhances parasympathetic activity. To directly test this
possibility we directly recorded glutamatergic EPSCs and
GABAergic and glycinergic IPSCs in NA CVNs in brainstem slices from WT and BDNF+/ mice. The GABA IPSC
frequency was signiﬁcantly greater in NA CVNs in slices
from BDNF+/ mice compared with WT mice (Fig. 4a).
The glutamate EPSC frequency was signiﬁcantly lower in
NA CVNs from BDNF+/ mice compared with WT mice
(Fig. 4b). There was no difference in glycinergic IPSC
frequency between WT and BDNF+/
mice (WT,
1.1  0.9 Hz; BDNF+/ , 1.0  0.4 Hz; p = 0.9). Collectively, these electrophysiological data suggest that BDNF
signaling sustains excitatory and blunts inhibitory neurotransmission to CVNs as BDNF haploinsufﬁciency reduces
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Fig. 1 Brain-derived neurotrophic factor (BDNF)-deﬁcient mice exhibit
an elevated heart rate, and intracerebroventricular administration of
BDNF lowers heart rate. (a) Heart rate was measured at 30 min
intervals during a 24 h period in six wild-type (WT) and six BDNFhaploinsufﬁcient (BDNF+/ ) mice. The inset graph shows the average
heart rates during the dark and light periods. The heart rate of WT and
BDNF+/ mice was signiﬁcantly higher during the night compared with
the day time (night vs. day, F(1,20) = 20.17, *p < 0.01). However,
BDNF+/ mice had a signiﬁcantly higher heart rate compared with WT
mice during both dark and light periods (WT vs. KO F(1,20) = 4.45,
p < 0.05), which was also indicated by the average for the dark and
light period (p < 0.05) (b and c). A single intraventricular bolus infusion
of BDNF results in a transient decrease in heart rate in WT (n = 12)
and BDNF+/ (n = 12) mice. Heart rate changes following infusion of
either phosphate-buffered saline (PBS) or BDNF at a dose of 2.5 lg in

WT and BDNF-deﬁcient mice. Heart rate change was calculated using
the average pre-infusion heart rate as the basal heart rate for each
mouse. The infusions were initiated in the late morning after recording
the baseline heart rate. Values are the mean and SEM. A repeated
three-way ANOVA analysis indicated a signiﬁcant change in heart rate
during the recorded period for all mice (Time, F(39) = 5.19, p < 0.01).
There was no difference between WT and BDNF+/ mice in response
to PBS infusion. However, BDNF infusion signiﬁcantly reduced heart
rate compared with PBS infusion (PBS vs. BDNF, F(1,20) = 12.15,
p < 0.01; time x PBS/BDNF F(1,39) = 2.61, p < 0.01). BDNF+/ mice
had a signiﬁcantly greater response to BDNF infusion compared with
WT mice (WT vs. BDNF+/ , F(1,20) = 5.15, p < 0.05). The larger
reduction in heart rate in response to BDNF infusion in BDNF+/ mice
was contributed by a signiﬁcantly higher basal heart rate in BDNF+/
mice compared with WT mice. Values are the mean and SEM.

CVN activity by increased inhibitory GABAergic and
diminished excitatory glutamatergic neurotransmission to
these neurons.

vagal neurons. Our measurements of heart rate in WT and
BDNF+/ mice, under basal conditions and after acute
intraventricular infusion of BDNF, provide evidence that
BDNF plays important roles in the autonomic regulation of
heart rate. The elevated resting heart rate in BDNF-haploinsufﬁcient mice suggests that BDNF signaling is necessary for
normal resting CNS-mediated cardioinhibitory parasympathetic drive to the heart. Consistent with the latter possibility,

Discussion
The present ﬁndings reveal a previously unknown role for
BDNF in the regulation of heart rate by brainstem cardiac
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Fig. 2 Brain-derived neurotrophic factor (BDNF) deﬁciency reduces
parasympathetic regulation of heart rate, while not affecting sympathetic activity or intrinsic heart rate. After recording baseline heart rate,
WT mice (n = 6) and BDNF+/ mice (n = 6) received intraperitoneal
injections of 2 mg/kg atropine, 2 mg/kg atenolol, or 30 mg/kg hexamethonium bromide. Heart rate was then measured at the indicated
time points. Values (mean and SEM) are expressed as change in
heart rate relative to the baseline (pre-drug). *p < 0.01. Atropine
signiﬁcantly increased heart rate in all mice in a time-dependent
180
WT
BDNF+/–

Δ Heart rate (bpm)

150
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0.5 h

1h
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Time after injection
Fig. 3 Central brain-derived neurotrophic factor (BDNF) infusion
eliminates the difference in heart rate response to atropine in
BDNF+/ mice compared with WT mice. BDNF was infused intracerebroventricularly at a dose of 3.0 lg in WT and BDNF+/ mice.
Three hours later atropine was injected (2 mg/kg, i.p.) and heart rates
were recorded at the indicated time points. Values are the mean and
SEM (six WT mice and six BDNF+/ mice).

we found that infusion of BDNF into the brain reduced heart
rate in both WT and BDNF+/ mice. Moreover, the elevation
in heart rate in response to atropine administration was

manner (F(3) = 30.35, p < 0.01). BDNF+/ mice had signiﬁcantly less
elevation of heart rate compared with the response of WT mice (F
(1,20) = 14.87, p < 0.01). Atenolol administration reduced heart rate in
all mice in a time-dependent manner (F(3) = 8.08, p < 0.01) and there
was no statistical difference in the response to atenolol between WT
mice and BDNF+/ mice. The ganglionic blocker hexamethonium was
used to examine the intrinsic heart rate. Hexamethonium increased
heart rate in both WT and BDNF+/ mice (time, F(3) = 20.3, p < 0.01),
with no differences between WT and BDNF+/ mice.

signiﬁcantly attenuated in BDNF+/ mice, and this abnormality was reversed by central infusion of BDNF. Collectively, these ﬁndings suggest that BDNF normally acts to
increase parasympathetic tone, thereby reducing resting heart
rate. Heart rate response to atenolol and hexamethonium was
not different in WT and BDNF+/ mice, indicating that
BDNF does not affect sympathetic stimulation of heart rate or
intrinsic beat frequency of the heart.
The differences in heart rate between wild-type and
BDNF+/ mice could result from developmental effects
and/or more acute effects of reduced BDNF signaling.
However, the fact that central infusion of BDNF normalized
heart rate in BDNF+/ mice within hours of administration
indicates that there is indeed an effect at the time of the
experiment. This does not rule out the possibility that BDNF
haploinsufﬁciency alters the development of neural circuits
that control heart rate, but does suggest that if this is the case,
then enhancement of BDNF signaling can rapidly overcome
any such developmental abnormality. In a previous study,
BDNF was infused into the lateral ventricles of adult rats,
and blood pressure and heart rate were measured 20 min
later; blood pressure increased, whereas heart rate was
unchanged (Wang et al. 2012). Focal injection of BDNF into
the medial nucleus of the tractus solitarius resulted in a rapid
(within seconds) increase in blood pressure and heart rate in
rats (Clark et al. 2011). On the other hand, injection of
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(a)

(b)

Fig. 4 The activation of nucleus ambiguus cardiac vagal neurons is
reduced in brain-derived neurotrophic factor (BDNF)-deﬁcient mice.
Spontaneous inhibitory GABAergic (a) and excitatory glutamatergic
excitatory post-synaptic currents (EPSCs) (b) were isolated and
recorded from labeled cardioinhibitory vagal neurons (CVNs) in the
nucleus ambiguus (NA) using the whole-cell patch-clamp conﬁguration. Representative traces from both wild-type (WT) and BDNF+/
mice are shown on the left, whereas average data are illustrated on the
right (*p < 0.05). BDNF+/ mice possessed signiﬁcantly lower frequencies of excitatory glutamate EPSCs than in WT mice, 1.9  0.5 Hz

(BDNF+/ ) versus 4.6  1 Hz (WT) (*p < 0.04). In contrast, BDNF+/
mice had signiﬁcantly higher levels of inhibitory GABA inhibitory
post-synaptic currents (IPSCs) events, 3.1  0.7 Hz (BDNF+/ )
versus 1.0  0.3 Hz (WT) (*p < 0.03). Values are the mean and
SEM. Inhibitory GABAergic events were recorded from nine neurons
from nine WT mice (one neuron per mouse) and from 10 neurons
from 10 BDNF+/ mice (one neuron per mouse). Glutamatergic
EPSCs were recorded from eight neurons from WT mice, and eight
neurons from BDNF+/ mice, in slices from seven WT and seven
BDNF+/ mice.

BDNF into the rostral ventrolateral medulla had no significant acute (seconds to minutes) effect on heart rate (Wang
and Zhou 2002). All the previous studies examined possible
acute effects of central BDNF administration on heart rate.
Our data suggest that BDNF signaling has a slower acting
(hours) negative chronotropic effect on heart rate that is
sustained for several hours after a single bolus infusion.
Although not investigated in this study, this time course is
consistent with a mechanism involving a change in gene
expression in response to BDNF receptor activation. It was
previously reported that BDNF can induce the expression of
choline acetyltransferase (Klein et al. 1999), which is one
potential explanation of enhanced cholinergic parasympathetic modulation of heart rate by BDNF.
Our electrophysiological data indicate that BDNF enhances
the activity state of brainstem parasympathetic cholinergic
CVNs in the NA that are known to control heart rate. The

frequency of glutamatergic EPSCs was decreased and the
frequency of GABAergic IPSCs was increased in NA CVNs
in brainstem slices from BDNF+/ mice. While the molecular
mechanisms underlying the effects of endogenous BDNF on
CVN activity are unknown, they are presumably mediated by
the high-afﬁnity BDNF receptor trkB and/or the p75 lowafﬁnity neurotrophin receptor. Brainstem cholinergic neurons
produce BDNF (Peiris et al. 2004) and express trkB (Tang
et al. 2010). Second, cell culture studies have shown that
BDNF stimulates the p75-mediated production and release of
acetylcholine from autonomic neurons resulting in a slowing
of spontaneous contraction of cardiac myocytes (Yang et al.
2002). It is also possible that BDNF acts on the neurons that
provide glutamatergic or GABAergic input to the CVNs.
Indeed, BDNF enhances glutamate release from pre-synaptic
terminals of hippocampal and visual cortex neurons (Alder
et al. 2005; Abidin et al. 2006), and BDNF also modiﬁes
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activity at GABAergic synapses (Wardle and Poo 2003). We
cannot rule out a contribution of an indirect effect of BDNF on
heart rate by, for example, an initial effect of BDNF on blood
pressure. However, the results of the brainstem slice electrophysiological data suggest that there is indeed an effect of
BDNF levels on the excitability of brainstem cardiovagal
inhibitory neurons that is entirely consistent with a more direct
effect of BDNF on these neurons. When taken together with
previous reports that BDNF can increase the expression
choline acetyltransferase and the vesicular acetylcholine
transporter, and enhance acetylcholine release from cholinergic neurons (Kn€usel et al. 1991; Takei et al. 1997; Klein
et al. 1999), our ﬁndings suggest that BDNF enhances
cholinergic regulation of heart rate.
BDNF is produced by neurons and released from them in a
synaptic activity-dependent manner (Matsuda et al. 2009).
Vigorous exercise and intermittent fasting stimulate BDNF
production in many different brain regions including those
involved in sensory–motor function and cognitive processing
(Lee et al. 2002; Duan et al. 2004; Gomez-Pinilla 2008;
Marais et al. 2009; Marlatt et al. 2012). Our ﬁndings suggest
that BDNF acts in the brainstem to enhance parasympathetic
activity and reduce resting heart rate. Because exercise and
intermittent fasting also reduce resting heart rate by a
mechanism involving enhanced vagal parasympathetic tone
(Shi et al. 1995; Wan et al. 2003; Mager et al. 2006), it will
be of considerable interest to determine whether BDNF
mediates the effects exercise and intermittent fasting on
autonomic regulation of heart rate. Finally, our ﬁndings
suggest a potential role for altered BDNF signaling in
disorders involving dysregulation of autonomic function.
Consistent with such a possibility, it was recently reported
that huntingtin mutant mice exhibit an elevated heart rate
associated with a signiﬁcant reduction in brainstem BDNF
levels (Grifﬁoen et al. 2012). In addition, subjects with a
common polymorphism in the BDNF gene exhibit an anxiety
phenotype and reduced heart rate variability associated with
decreased parasympathetic activity (Yang et al. 2010).
Moreover, administration of paroxetine, a serotonin-selective
reuptake inhibitor that increases BDNF production in the
brain (Duan et al. 2004), increases parasympathetic control of
heart rate in humans suffering from panic disorder (Tucker
et al. 1997).
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